A2B Adenosine Receptor as a novel target in cancer immunotherapy: validation and optimization of new ligands

• Autores: Rubén Prieto Díaz
• Directores de la Tesis: Eddy Sotelo Pérez (dir. tes.)
• Lectura: En la Universidade de Santiago de Compostela ( España ) en 2023
• Idioma: inglés
• Tribunal Calificador de la Tesis: Santiago Vázquez Cruz (presid.), Julio César Castro Palomino Laria (secret.), María Laura Bolognesi (voc.)
• Programa de doctorado: Programa de Doctorado en Investigación y Desarrollo de Medicamentos por la Universidad de Santiago de Compostela
• Materias:
  • Química
    • Química orgánica
• Enlaces
  • Tesis en acceso abierto en: MINERVA
• Resumen

  • This doctoral thesis focuses on the study of purinergic signaling in cancer, specifically targeting adenosine receptors. The main objective is the development of potent and selective nonxanthine- based antagonists for adenosine A2B receptors, with potential applications in cancer-targeted therapies. Molecular design strategies, synthesis, biological evaluation, structureactivity relationships, enantiospecific recognition and molecular modeling are explored. To the end, a rational method for dual A2A/A2B antagonists were obtained. The optimization and preclinical validation of new ligands for cancer (immuno)therapy are investigated, revealing promising data in terms of pharmacokinetics and pharmacodynamics.